Technical Analysis for ADMP - Adamis Pharmaceuticals Corporation

Grade Last Price % Change Price Change
grade F 0.74 -1.33% -0.01
ADMP closed down 1.33 percent on Thursday, September 19, 2019, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***
3 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ADMP trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness -1.33%
Wide Bands Range Expansion -1.33%
Down 3 Days in a Row Weakness -1.33%
Down 4 Days in a Row Weakness -1.33%
Down 5 Days in a Row Weakness -1.33%

Older signals for ADMP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
ADMP Chart by TradingView
Basic chart:
Profile
Adamis Pharmaceuticals Corporation, a biopharmaceutical company, engages in the development and commercialization of specialty pharmaceutical products in the therapeutic areas of oncology, immunology and infectious diseases, and allergy and respiratory. The company focuses on the development of small molecule compounds, which comprise APC-100, APC-200, and APC-300 for the treatment of human prostate cancer; telomerase vaccine technologies; and other vaccine technologies for providing protection against various viral infectious agents. Its products under development also comprise TeloB-VAX, a novel cell-based vaccine product for prostate cancer; and Savvy(C31G), a contraceptive gel. The company's allergy and respiratory product pipeline includes Epinephrine Injection USP 1, a pre-filled single dose syringe product for use in the emergency treatment of extreme acute allergic reactions or anaphylactic shock; APC-1000, a steroid hydrofluoroalkane (HFA) metered dose inhaler product for asthma and chronic obstructive pulmonary disease; APC-2000, a generic HFA bronchodilator; and APC-3000, an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis. It has a strategic manufacturing, supply, and product development agreement with Beximco Pharmaceuticals Ltd. The company is based in San Diego, California.
Medicine Health Biopharmaceutical Manufacturing Medical Specialties Infectious Diseases Pharmaceutical Products Prostate Cancer Respiratory Therapy Asthma Allergy Dosage Forms Chronic Obstructive Pulmonary Disease Smoking Cessation Emergency Treatment Inhaler Metered Dose Inhaler Rhinitis
Is ADMP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 12 Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): What Does Its Beta Value Mean For Your Portfolio?
Sep 4 Adamis Updates Investors On SYMJEPI Launch And ZIMHI PK Study, While The Stock Hits A New 52-Week Low
Sep 3 Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate
Aug 28 Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI
Aug 26 Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
Aug 19 Adamis: Past Hurdles Could Lead To A Successful Future
Aug 14 Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary
Aug 9 Edited Transcript of ADMP earnings conference call or presentation 8-Aug-19 9:00pm GMT
Aug 9 Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q2 2019 Results - Earnings Call Transcript
Aug 9 Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
See more ADMP news...
Indicators
Indicator Value
52 Week High 4.25
52 Week Low 0.7
Average Volume 716,008
200-Day Moving Average 1.9348
50-Day Moving Average 1.0239
20-Day Moving Average 0.8552
10-Day Moving Average 0.7912
Average True Range 0.071
ADX 26.11
+DI 15.3281
-DI 29.0761
Chandelier Exit (Long, 3 ATRs ) 0.897
Chandelier Exit (Short, 3 ATRs ) 0.913
Upper Bollinger Band 1.0544
Lower Bollinger Band 0.656
Percent B (%b) 0.21
BandWidth 46.585594
MACD Line -0.079
MACD Signal Line -0.0791
MACD Histogram 0.0
Fundamentals Value
Market Cap 23.2 Million
Num Shares 31.4 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -0.85
Price-to-Sales 14.86
Price-to-Book 4.42
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.80
Resistance 3 (R3) 0.80 0.79 0.79
Resistance 2 (R2) 0.79 0.77 0.79 0.79
Resistance 1 (R1) 0.76 0.76 0.76 0.76 0.78
Pivot Point 0.75 0.75 0.74 0.75 0.75
Support 1 (S1) 0.72 0.73 0.72 0.72 0.70
Support 2 (S2) 0.71 0.72 0.71 0.69
Support 3 (S3) 0.68 0.71 0.69
Support 4 (S4) 0.68